Novel approaches in the treatment of lupus nephritis

Lupus

Volumn 7, Issue 9, 1998, Pages 644-648

  Illei, G G ^a,b   Klippel, J H ^a  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Biological products; Clinical trial; Human; Systemic lupus erythematosus; Therapy

Indexed keywords

CLADRIBINE; CYCLOPHOSPHAMIDE; DEOXYRIBONUCLEASE; FLUDARABINE; GLYCOPROTEIN GP 39; INTERLEUKIN 10; LEFLUNOMIDE; MEMBRANE ANTIGEN; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTRALIZING ANTIBODY; NUCLEOSIDE ANALOG; THROMBOXANE A2;

B LYMPHOCYTE; BONE MARROW TRANSPLANTATION; HUMAN; IMMUNE COMPLEX DEPOSITION; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE CLONE; LYMPHOCYTE SUBPOPULATION; MONONUCLEAR CELL; ORAL DRUG ADMINISTRATION; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; CD40 LIGAND; COMPLEMENT C5; HUMANS; LUPUS NEPHRITIS; LYMPHOCYTES; MEMBRANE GLYCOPROTEINS; OLIGONUCLEOTIDES;

EID: 0032428842     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120398678920794     Document Type: Review

References (59)

1. Nelson JL et al. Pre-existing autoimmune disease in patients with long-term survival after allogeneic bone marrow transplantation. J Rheumatol Suppl 1997; 48: 23-29.
2. Passweg JR et al. Autologous stem cell transplantation for autoimmune disease. A preliminary report. Blood 1997; 10 (Suppl. 1): abstract 233.
3. Brodsky RA et al. High-dose cyclophosphamide (Cy) without bone marrow transplant (BMT) for refractory severe autoimmune diseases (SADS). Blood 1997; 10 (Suppl. 1): abstract 234.
4. Guchelaar HJ, Richel DJ, Schaafsma MR. Clinical and toxicological aspects of the anti-neoplastic drug cladribine: a review. Ann Hematol 1994; 69: 223-230.
5. Davis JC Jr et al. A pilot study of 2-chloro-2′-deoxyadenosine in the treatment of systemic lupus erythematosus-associated glomerulonephritis. Arthritis Rheum 1998; 41: 335-343.
6. Plunkett W, Gandhi V. Nucleoside analogs; cellular pharmacology, mechanisma of action and strategies for combination therapy. In: Cheson Keating, Plunkett (eds) Nucleoside Analogs in Cancer Therapy. Marcel Dekker: New York, 1997, p 1.
7. O'Brien S, Kantarjian H, Beran M. Fludarabine (FAMP) and cyclophosphamide therapy in chronic lymphocytic leukemia (CLL). Ann Oncol 1994; 7 (Suppl. 3): 34 (abstract).
8. Ransom JT. Mechanism of action of mycophenolate mofetil. Ther Drug Monit 1995; 17: 681-684.
9. Laurent AF, Dumont S, Poindron P, Muller CD. Mycophenolic acid suppresses protein N-linked glycosylation in human monocytes and their adhesion to endothelial cells and to some substrates. Exp Hematol 1996; 24: 59-67.
10. Corna D et al. Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. Kidney Int 1997; 51: 1583-1589.
11. Briggs WA, Choi MJ, Scheel PJ Jr. Successful mycophenolate mofetil treatment of glomerular disease. Am J Kidney Dis 1998; 31: 213-217.
12. Dooley MA et al. Mycophenylate mofetil therapy in resistant or relapsing diffuse proliferative lupus nephritis (SLE-DPGN) following cyclophosphamide (CyP) therapy. Arthritis Rheum 1997; 40 (Suppl.): S58 (abstract).
13. Soga T, Ishigatsubo Y, Kitamura H, Okubo T. Effect of mizoribine on pulmonary lesions in MRL/lpr/lpr mice. Autoimmunity 1996; 25: 9-18.
14. Iwasaki T et al. A case of systemic lupus erythematosus (SLE) successfully treated with mizoribine. Ryumachi 1994; 34: 885-889.
15. Davis JP et al. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry 1996; 35: 1270-1273.
16. Cao WW et al. A novel mechanism of action of the immunomodulatory drug, leflunomide: augmentation of the immunosuppressive cytokine TGF-beta 1 and suppression of the immunostimulatory cytokine IL-2. Transplant Proc 1996; 28: 3079-3080.
17. Bartlett RR, Popovic S, Raiss RX. Development of autoimmunity in MRL/lpr mice and the effects of drugs on this murine disease. Scand J Rheumatol Suppl 1988; 75: 290-299.
18. Mladenovic V et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study. Arthritis Rheum 1995; 38: 1595-1603.
19. Metzler C, Reinhold-Keller E, Schmitt W, Gross WL. Maintenance of remission with leflunomide in 11 patients with Wegener's granulomatosis (WG). Arthritis Rheum 1997; 40 (Suppl.): S165 (abstract).
20. Strand V. Approaches to the management of systemic lupus erythematosus. Curr Opin Rheumatol 1997; 9: 410-420.
21. Wofsy D. Treatment of murine lupus with anti-CD4 monoclonal antibodies. Immunol Ser 1993; 59: 221-236.
22. Carteron NL, Schimenti CL, Wofsy D. Treatment of murine lupus with F(ab′)2 fragments of monoclonal antibody to L3T4. Suppression of autoimmunity does not depend on T helper cell depletion. J Immunol 1989; 142: 1470-1475.
23. Hiepe F et al. Treatment of severe systemic lupus erythematosus (SLE) with monoclonal anti-CD4 antibodies (MAX.16H5). Arthritis Rheum 1995; 38 (Suppl.): S303 (abstract).
24. Stafford FJ et al. A pilot study of anti-CD5 ricin A chain immunoconjugate in systemic lupus erythematosus. J Rheumatol 1994; 21: 2068-2070.
25. Hanly JG et al. Immunomodulating effects of synchronised plasmapheresis and intravenous bolus cyclophosphamide in systemic lupus erythematosus. Lupus 1995; 4: 457-463.
26. Euler HH, Guillevin L. Plasmapheresis and subsequent pulse cyclophosphamide in severe lupus erythematosus. An interim report of the Lupus Plasmapheresis Study Group. Ann Med Interne (Paris) 1994; 145: 296-302.
27. Dau PC, Callahan J, Parker R, Golbus J. Immunologic effects of plasmapheresis synchronized with pulse cyclophosphamide in systemic lupus erythematosus. J Rheumatol 1991; 18: 270-276.
28. Schroeder JO, Euler HH, Loffler H. Synchronization of plasmapheresis and pulse cyclophosphamide in severe systemic lupus erythematosus. Ann Intern Med 1987; 107: 344-346.
29. Euler HH et al. Treatment-free remission in severe systemic lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamide. Arthritis Rheum 1994; 37: 1784-1794.
30. Wallace DJ et al. A randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis. Lupus 1998; 7 (Suppl. 1): 79 (abstract).
31. Schroeder JO et al. Plasmapheresis and subsequent pulse cyclophosphamide in severe systemic lupus erythematosus. Preliminary results of the LPSG-Ttrial. Arthritis Rheum 1997; 40 (Suppl.): S325 (abstract).
32. Aringer M, Smolen JS, Graninger WB. Severe infections in plasmapheresis-treated systemic lupus erythematosus. Arthritis Rheum 1998; 41: 414-420.
33. Chitrabamrung S, Rubin RL, Tan EM. Serum deoxyribonuclease I and clinical activity in systemic lupus erythematosus. Rheumatol Int 1981; 1: 55-60.
34. Macanovic M, Lachmann PJ. Measurement of deoxyribonuclease I (DNase) in the serum and urine of systemic lupus erythematosus (SLE)-prone NZB/NZW mice by a new radial enzyme diffusion assay. Clin Exp Immunol 1997; 108: 220-226.
35. Macanovic M et al. The treatment of systemic lupus erythematosus (SLE) in NZB/W F1 hybrid mice; studies with recombinant murine DNase and with dexamethasone. Clin Exp Immunol 1996; 106: 243-252.
36. Davis JC et al. Phase lb study of recombinant human DNase (rhDNase) in lupus nephritis. Arthritis Rheum 1997; 40 (Suppl.): S59 (abstract).
37. Weisbart RH et al. A conserved anti-DNA antibody idiotype associated with nephritis in murine and human systemic lupus erythematosus. J Immunol 1990; 144: 2653-2658.
38. Lee M et al. Updated Phase I clinical results with an idiotypic vaccine (3E10) for systemic lupus erythematosus (SLE). Arthritis Rheum 1995; 38 (Suppl.): S303 (abstract).
39. Gaynor B et al. Peptide inhibition of glomerular deposition of an anti-DNA antibody. Proc Natl Acad Sci USA 1997; 94: 1955-1960.
40. Weisman MH, Bluestein HG, Berner CM, de Haan HA. Reduction in circulating dsDNA antibody liter after administration of LJP 394. J Rheumatol 1997; 24: 314-318.
41. Wang Y et al. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci USA 1996; 93: 8563-8568.
42. Early GS, Zhao W, Burns CM. Anti-CD4-O ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response. J Immunol 1996; 157: 3159-3164.
43. Mohan C, Shi Y, Laman JD, Datta SK. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol 1995; 154: 1470-1480.
44. Koshy M, Berger D, Crow MK. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 1996; 98: 826-837.
45. Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 1996; 97: 2063-2073.
46. Llorente L et al. Dysregulation of interleukin-10 production in relatives of patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1429-1435.
47. Park YB et al. Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 1998; 16: 283-288.
48. Houssiau FA et al. Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus 1995; 4: 393-395.
49. Hagiwara E, Gourley MF, Lee S, Klinman DK. Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10:interferon-gamma-secreting cells in the peripheral blood. Arthritis Rheum 1996; 39: 379-385.
50. Kalechman Y et al. Delay in the onset of systemic lupus erythematosus following treatment with the immunomodulator AS101: association with IL-10 inhibition and increase in TNF-alpha levels. J Immunol 1997; 159: 2658-2667.
51. Ishida H et al. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med 1994; 179: 305-310.
52. Patrono C et al. Functional significance of renal prostacyclin and thromboxane A2 production in patients with systemic lupus erythematosus. J Clin Invest 1985; 76: 1011-1018.
53. Kimberly RP et al. Elevated urinary prostaglandins and the effects of aspirin on renal function in lupus erythematosus. Ann Intern Med 1978; 89: 336-341.
54. Pierucci A et al. Improvement of renal function with selective thromboxane antagonism in lupus nephritis. N Engl J Med 1989; 320: 421-425.
55. Spurney RF et al. Thromboxane receptor blockade reduces renal injury in murine lupus nephritis. Kidney Int 1992; 41: 973-982.
56. Salvati P et al. Long-term thromboxane-synthase inhibition prolongs survival in murine lupus nephritis. Kidney Int 1995; 47: 1168-1175.
57. Matsuo Y et al. Antiproteinuric effect of a thromboxane receptor antagonist, S-1452, on rat diabetic nephropathy and murine lupus nephritis. Pharmacology 1995; 50: 1-8.
58. Yoshida T et al. Improvement of renal function with a selective thromboxane A2 synthetase inhibitor, DP-1904, in lupus nephritis [see comments]. J Rheumatol 1996; 23: 1719-1724.
59. Yoshida T, Ichikawa Y, Tojo T, Homma M. Abnormal prostanoid metabolism in lupus nephritis and the effects of a thromboxane A2 synthetase inhibitor, DP-1904. Lupus 1996; 5: 129-138.